GlobalData on MSN4d
Bio-Thera signs US deal with Intas for golimumab biosimilarBio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback